Siemens Healthcare said that initial research of its new PET imaging biomarker has yielded promising results.
Developed in collaboration with Fox Chase Cancer Center in Philadelphia, the agent is designed to capture and quantify the cellular expression of carbonic anhydrase IX (CA-IX), which has been linked to hypoxia and tumor growth and invasion, according to the Malvern, PA-based vendor.
Phase 0 research presented today at the World Molecular Imaging Congress in Montreal found that biodistribution of the agent was recorded at safe levels for human use. In addition, the agent was found to be stable for imaging at 133 minutes postinjection, Siemens said. Further research with patients is in progress.
Related Reading
Rutgers, Siemens, Penn net MRI research grant, September 23, 2009
Siemens donates DR in children's benefit, September 17, 2009
Siemens inks isotope pact with UNM, September 16, 2009
Siemens unveils women's imaging US unit, September 14, 2009
Siemens signs deal with SurgiVision, September 8, 2009
Copyright © 2009 AuntMinnie.com
